The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
Open accessAbstract
The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus chemotherapy were included and clinical response was evaluated according to response evaluation criteria in solid tumours (RECIST). Tumours were screened for KRAS mutations using first direct sequencing, then two sensitive methods based on SNaPshot and PCR-ligase chain reaction (LCR) assays. Clinical response was evaluated according to gene mutations using the Fisher exact test. Times to progression (TTP) were calculated using the Kaplan-Meier method and compared with log-rank test. A KRAS mutation was detected in 22 out of 59 tumours and, in six cases, was missed by sequencing analysis but detected using the SNaPshot and PCR-LCR assays. Remarkably, no KRAS mutation was found in the 12 patients with clinical response. KRAS mutation was associated with disease progression (P=0.0005) and TTP was significantly decreased in mutated KRAS patients (3 vs 5.5 months, P=0.015). Our study confirms that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as major determinants of primary resistance to cetuximab or panitumumab [17, 27-29].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Kabbinavar, F. F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Liebérman, G., Griffing, S., & Bergsland, E. K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,711
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,080
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
LigAmp for sensitive detection of single-nucleotide differences
Shi, C., Eshleman, S. H., Jones, D. C., Fukushima, N., Li, H., Parker, A. R., Yeo, C. J., Hruban, R. H., Goggins, M., & Eshleman, J. R. (2004) · Nature Methods · doi:10.1038/nmeth713 · Cited by 127
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 734
Erben, P., Ströbel, P., Horisberger, K., Popa, J., Bohn, B., Hanfstein, B., Kähler, G. F. B. A., Kienle, P., Post, S., Wenz, F. K., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.043 · Cited by 53
Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer
Lefébure, B., Charbonnier, F., Fiore, F. D., Tuech, J., Pessot, F. L., Michot, F., Michel, P., & Frébourg, T. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c35c87 · Cited by 53
Self-citationLaboratory methods forKRASmutation analysis
Anderson, S. M. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.42 · Cited by 53
Peeters, M., BALFOUR, J., & Arnold, D. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03717.x · Cited by 52
Yang, M.-J., Chiu, H., Wang, H., Yen, L.-C., Tsao, D., Hsiao, C.-P., Chen, Y., Wang, J., & Lin, S. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0831-8 · Cited by 52
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
Seow, H. F., Yip, W. K., & Fifis, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95101 · Cited by 54
Chang, D. Z., Kumar, V. S., Ma, Y., Li, K., & Kopetz, S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-18 · Cited by 52
Ciardiello, F., Tejpar, S., Normanno, N., Mercadante, D., Teague, T., Wohlschlegel, B., & Cutsem, E. V. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0181-x · Cited by 51
Kim, H. S., Heo, J. S., Lee, J. Y., Lee, J., Lee, M., Lim, S. H., Lee, W. Y., Kim, S. H., Park, Y. A., Cho, Y. B., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2141-4 · Cited by 51
Mutation spectra of RAS gene family in colorectal cancer
Chang, Y.-Y., Lin, P.-C., Lin, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., Liang, W.-Y., & Chang, S. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.02.013 · Cited by 51
Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51
Pharmacogenetics of EGFR and VEGF inhibition
Pander, J., Gelderblom, H. A. J., & Guchelaar, H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.016 · Cited by 49
Russo, A. D., Rizzo, S., Bronte, G., Silvestris, N., Colucci, G., Gebbia, N., Bazan, V., & Fulfaro, F. (2009) · Oncology · doi:10.1159/000258497 · Cited by 51
Mordant, P., Loriot, Y., Leteur, C., Caldéraro, J., Bourhis, J., Wislez, M., Soria, J., & Deutsch, É. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1014 · Cited by 50
Amicarelli, G., Shehi, E., Makrigiorgos, G. M., & Adlerstein, D. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm809 · Cited by 50
Magnin, S., Viel, E., Baraquin, A., Valmary‐Degano, S., Kantelip, B. M., Prétet, J., Mougin, C., Bigand, M., Girardo, B., Borg, C., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.05.010 · Cited by 49
Perkins, G., Lièvre, A., Ramacci, C., Méatchi, T., de Reyniès, A., Emile, J., Boige, V., Tomasic, G., Bachet, J., Bibeau, F., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25152 · Cited by 54
(2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7_14 · Cited by 49
Saki, M. R., Toulany, M., & Rodemann, H. P. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.023 · Cited by 48
Arnold, D., Höhler, T., Dittrich, C., Lordick, F., Seufferlein, T. T. W., Riemann, J. F., Wöll, E., Herrmann, T. R. W., Zubel, A., & Schmoll, H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn150 · Cited by 48
Mlakar, V., Berginc, G., Volavšek, M., Štor, Z., Rems, M., & Glavač, D. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-282 · Cited by 48
Yu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Guedes, J. G., Veiga, I., Rocha, P., Pinto, P., Pinto, C., Pinheiro, M., Peixoto, A., Fragoso, M., Raimundo, A. C., Ferreira, P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-169 · Cited by 48
Winder (2009) · Oncology Reports · doi:10.3892/or_00000352 · Cited by 47
Sarasqueta, A. F., Moerland, E., de Bruyne, H., de Graaf, H., Vrancken, T., van Lijnschoten, G., & van den Brule, A. J. C. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.10.006 · Cited by 47
Therapeutic modulation of k-ras signaling in colorectal cancer
Krens, L. L., Baas, J. M., Gelderblom, H. A. J., & Guchelaar, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.012 · Cited by 46
Packham, D., Ward, R. L., Lin, V. A., Hawkins, N. J., & Hitchins, M. P. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e318182af52 · Cited by 47
Morelli, M. P., Tentler, J. J., Kulikowski, G. N., Tan, A. C., Bradshaw‐Pierce, E. L., Pitts, T. M., Brown, A. M., Nallapareddy, S., Arcaroli, J. J., Serkova, N. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1507 · Cited by 46
Scartozzi, M., Giampieri, R., Maccaroni, E., Mandolesi, A., Giustini, L., Silva, R., Zaniboni, A., Biscotti, T., Biagetti, S., Galizia, E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr558 · Cited by 43
Mutated RAS: Targeting the “Untargetable” with T Cells
Chatani, P. D., & Yang, J. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2138 · Cited by 45
Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., Lodi, F., Nicoletti, G., Landuzzi, L., Lollini, P., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn625 · Cited by 45
KRAS mutation testing in clinical practice
Perincheri, S., & Hui, P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.986102 · Cited by 46
Santini, D., Spoto, C., Loupakis, F., Vincenzi, B., Silvestris, N., Cremolini, C., Canestrari, E., Graziano, F., Galluccio, N., Salvatore, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq318 · Cited by 46
Xu, Q., Xu, A. T., Zhu, M., Tong, J. L., Xi Tao, X. U., & Ran, Z. H. (2013) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12063 · Cited by 49
Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives
Hohla, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6102 · Cited by 45
Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors
Goranova, T., Ohue, M., Shimoharu, Y., & Kato, K. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9381-0 · Cited by 45
Kit, A. H., Mazaleyrat, N., Daunay, A., Nielsen, H. M., Terris, B., & Tost, J. (2013) · Human Mutation · doi:10.1002/humu.22427 · Cited by 45
Eng, C. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0167 · Cited by 45
Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke, W. C. M., & Heinemann, V. (2010) · PubMed · Cited by 45
Larki, P., Gharib, E., Taleghani, M. Y., Khorshidi, F., Mojarad, E. N., & Asadzadeh Aghdaei, H. (2017) · Europe PMC (PubMed Central) · doi:10.22074/cellj.2017.5123 · Cited by 44
Smilek, P., Neuwirthová, J., Jarkovský, J., Dušek, L., Rottenberg, J., Kostřica, R., Srovnal, J., Hajdúch, M., Drábek, J., & Klozar, J. (2012) · Neoplasma · doi:10.4149/neo_2012_065 · Cited by 45
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application
Lee, S., & McLeod, H. L. (2010) · The Journal of Pathology · doi:10.1002/path.2766 · Cited by 44
Clinical Biomarkers in Oncology
Roock, W. D., Biesmans, B., Schutter, J. D., & Tejpar, S. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256319 · Cited by 44
Kim, J. C., Kim, S., Cho, D. H., Ha, Y. J., Choi, E. Y., Kim, C. W., Roh, S. A., Kim, T. W. B., Ju, H., & Kim, Y. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1907 · Cited by 42
Ouwerkerk, J., & Boers-Doets, C. B. (2010) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2010.03.004 · Cited by 43
Fouz, M. F., & Appella, D. H. (2020) · Molecules · doi:10.3390/molecules25040786 · Cited by 42
Raoul, J., Laethem, J. V., Peeters, M., Brézault, C., Husseini, F., Cals, L., Nippgen, J., Loos, A., & Rougier, P. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-112 · Cited by 43
The inhibitory effects of 5‐hydroxy‐3,6,7,8,3′,4′‐hexamethoxyflavone on human colon cancer cells
Qiu, P., Guan, H., Dong, P., Guo, S., Zheng, J., Li, S., Chen, Y., Ho, C., Pan, M., McClements, D. J., et al. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100070 · Cited by 42
Molecular Predictors of Response to Chemotherapy in Colorectal Cancer
Dienstmann, R., Vilar, E., & Tabernero, J. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212f844 · Cited by 43
Functional Genomics Applied to Cardiovascular Medicine
Cappola, T. P., & Margulies, K. B. (2011) · Circulation · doi:10.1161/circulationaha.111.027300 · Cited by 42
Jeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S. Y., Kim, K., Yoon, Y., Kim, D., Chun, S., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.005 · Cited by 43
Wu, S., Gan, Y., Wang, X., Liu, J., Li, M., & Tang, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1400-x · Cited by 44
Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
Milano, G. A., Étienne-Grimaldi, M.-C., Dahan, L., Francoual, M., Spano, J., Benchimol, D., Chazal, M., Létoublon, C., André, T., Gilly, F. N., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn416 · Cited by 41
The role of tumor markers and biomarkers in colorectal cancer
Lech, G., Słotwiński, R., & Krasnodebski, I. W. (2013) · Neoplasma · doi:10.4149/neo_2014_003 · Cited by 41
Lin, A. Y., Buckley, N. S., Lu, A.-T. T., Kouzminova, N. B., & Salpeter, S. R. (2011) · Clinical Colorectal Cancer · doi:10.3816/ccc.2011.n.009 · Cited by 45
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
Pérez, R., Moreno, E., Garrido, G., & Crombet, T. (2011) · Cancers · doi:10.3390/cancers3022014 · Cited by 41
KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. G. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e31819e3202 · Cited by 39
Dobi, E., Monnien, F., Kim, S. C. H., Ivanaj, A., N'Guyen, T., Demarchi, M., Adotévi, O., Thiery-Vuillemin, A., Jary, M., Kantelip, B. M., et al. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.09.002 · Cited by 43
Wang, Z., Gao, Q., & Fang, J. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1886-y · Cited by 43
Promoter CpG Island Methylation Markers in Colorectal Cancer: The Road Ahead
Draht, M. X. G., Riedl, R. G., Niessen, H. E. C., Carvalho, B. G., Meijer, G. A., Herman, J. G., van Engeland, M., Melotte, V., & Smits, K. M. (2012) · Epigenomics · doi:10.2217/epi.12.9 · Cited by 40
KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer
Herreros‐Villanueva, M., Rodrigo, M., Claver, M., Múñiz, P., Lastra, E., Girón, C. G., & del Corral, M. J. C. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0232-x · Cited by 41
Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine
Chauvin, A., & Boisvert, F. (2018) · Proteomes · doi:10.3390/proteomes6040049 · Cited by 41
Targeting the epidermal growth factor receptor in metastatic colorectal cancer
Ng, K., & Zhu, A. X. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.09.006 · Cited by 42
Kelley, R. K., Bebber, S. L. V., Phillips, K. A., & Venook, A. P. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0004 · Cited by 40
Costa, J., Cabaret, O., Moukoury, S., & Bretagne, S. (2011) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2011.06.017 · Cited by 39
Lurje, G., Schiesser, M., Hoffmann, A.-C., & Schneider, P. M. (2009) · Journal of Oncology · doi:10.1155/2010/392652 · Cited by 38
Kriegsmann, M., Arens, N., Endris, V., Weichert, W., & Kriegsmann, J. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0364-3 · Cited by 39
Soeda, H., Shimodaira, H., Watanabe, M., Suzuki, T., Gamoh, M., Mori, T., Komine, K., Iwama, N., Kato, S., & Ishioka, C. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0422-8 · Cited by 37
ERBBs in the gastrointestinal tract: Recent progress and new perspectives
Fiske, W. H., Threadgill, D. W., & Coffey, R. J. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.043 · Cited by 38
Boissière‐Michot, F., Lopez‐Crapez, E., Frugier, H., Berthe, M.-L., Ho-Pun-Cheung, A., Assénat, E., Maudelondé, T., Lamy, P., & Bibeau, F. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.210 · Cited by 37
Meßner, I., Cadeddu, G., Huckenbeck, W., Knowles, H. J., Gabbert, H. E., Baldus, S. E., & Schaefer, K. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1319-7 · Cited by 37
Thaler, J., Karthaus, M., Mineur, L., Greil, R., Letocha, H., Hofheinz, R., Fernebro, E., Gamelin, E. C., Baños, A., & Köhne, C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-438 · Cited by 37
Pharmacogenomics of chemotherapeutic susceptibility and toxicity
Moen, E. L., Godley, L. A., Zhang, W., & Dolan, M. E. (2012) · Genome Medicine · doi:10.1186/gm391 · Cited by 37
Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.
Mariani, P., Lae, M. E., Degeorges, A., Cacheux, W., Lappartient, E., Margogne, A., Pierga, J., Girre, V., Mignot, L., Falcou, M. C., et al. (2010) · PubMed · Cited by 37
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review)
Libra, M. (2010) · Molecular Medicine Reports · doi:10.3892/mmr.2010.408 · Cited by 37
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer
Pinto, P., Rocha, P., Veiga, I., Guedes, J. G., Pinheiro, M., Peixoto, A., Pinto, C., Fragoso, M., Sanches, E., Araújo, A., et al. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.07.003 · Cited by 37
Bar‐Ad, V., Zhang, Q., Harari, P. M., Axelrod, R. S., Rosenthal, D. I., Trotti, A., Jones, C. U., Garden, A. S., Song, G., Foote, R. L., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.03.011 · Cited by 37
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
Ganti, A. K., & Reade (2009) · Biologics · doi:10.2147/btt.2009.3119 · Cited by 39
Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new?
Ponz‐Sarvisé, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i44.5877 · Cited by 37
de Reyniès, A., Boige, V., Milano, G. A., Faivre, J., & Laurent‐Puig, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9186 · Cited by 37
Somatic alterations as the basis for resistance to targeted therapies
Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 36
Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma
Wang, W., Chien, Y., Wong, Y., Lin, Y., & Lin, J. (2011) · Head & Neck · doi:10.1002/hed.21792 · Cited by 36
Chen, Z., Duldulao, M. P., Li, W., Lee, W., Kim, J., & García‐Aguilar, J. (2011) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.02.024 · Cited by 36
Cetuximab in metastatic colorectal cancer
Broadbridge, V. T., Karapetis, C. S., & Price, T. J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.25 · Cited by 36
Cui, D., Cao, D., Yang, Y., Qiu, M., Huang, Y., & Cheng, Y. (2014) · Molecular Biology Reports · doi:10.1007/s11033-013-2974-8 · Cited by 36
Shankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 36
Caruso, M., Moore, J., Goodall, G. J., Thomas, M., Phillis, S., Tyskin, A., Cheetham, G., Lerda, N., Takahashi, H., & Ruszkiewicz, A. (2009) · Virchows Archiv · doi:10.1007/s00428-009-0731-0 · Cited by 34
Forest, F., Yvorel, V., Karpathiou, G., Stachowicz, M., Vergnon, J., Fournel, P., Tiffet, O., Trombert, B., & Péoc’h, M. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.10.006 · Cited by 35
Mutation detection and molecular targeted tumor therapies
Wang, Y., & Chen, Z. (2020) · STEMedicine · doi:10.37175/stemedicine.v1i1.11 · Cited by 35
Integration of panitumumab into the treatment of colorectal cancer
Grávalos, C., Cassinello, J., Alfonso, P. G., & Jimeno, A. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.06.005 · Cited by 35
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
DeStefanis, R. A., Kratz, J. D., Emmerich, P. B., & Deming, D. A. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00430-6 · Cited by 34
Huang, L., Liu, Z., Deng, D., Tan, A., Liao, M., Mo, Z., & Yang, X. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.40728 · Cited by 37
Sakane, T., Murase, T., Okuda, K., Saida, K., Masaki, A., Yamada, T., Saito, Y., Nakanishi, R., & Inagaki, H. (2019) · Histopathology · doi:10.1111/his.13936 · Cited by 34
Tourneau, C. L., Vidal, L., & Siu, L. L. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.04.001 · Cited by 34
Fiore, F. D., Charbonnier, F., Lefébure, B., Laurent, M., Pessot, F. L., Michel, P., & Frébourg, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604451 · Cited by 34
Self-citationElez, E., Hendlisz, A., Delaunoit, T., Sastre, J., Cervantes, A., Varea, R., Chao, G., Wallin, J., & Tabernero, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.480 · Cited by 33
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
Kawamoto, Y., Tsuchihara, K., Yoshino, T., Ogasawara, N., Kojima, M., Takahashi, M., Ochiai, A., Bando, H., Fuse, N., Tahara, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.218 · Cited by 33
Impact of KRAS Mutations on Management of Colorectal Carcinoma
Sullivan, K. M., & Kozuch, P. S. (2011) · Pathology Research International · doi:10.4061/2011/219309 · Cited by 36
Costa, J., Garcia‐Hermoso, D., Olivi, M., Cabaret, O., Farrugia, C., Lecellier, G. J., Dromer, F., & Bretagne, S. (2010) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2010.01.002 · Cited by 33
Khan, S. A., Zeng, Z., Shia, J., & Paty, P. B. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0166-2 · Cited by 33
Metadata
- Authors
- Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., Queuniet, A. M., Paillot, B., Sabourin, J. C., Michot, F., Michel, P., & Frebourg, T.
- Affiliations
- Centre Hospitalier Universitaire de Rouen (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Venue
- British Journal of Cancer
- Published
- 2007-03-20
- Volume
- 96
- Issue
- 8
- Pages
- 1166-1169
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360149
- OpenAlex
- W1999250974
- Cited by
- 734
- References
- 12
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 10 · 2022: 10 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 14 · 2017: 21 · 2016: 30 · 2015: 33 · 2014: 54 · 2013: 52 · 2012: 62
- FWCI
- 51.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National Du Cancer
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- KRAS mutation, metastatic colorectal cancer, cetuximab, anti-EGFR therapy, predictive biomarkers, chemotherapy-refractory cancer, SNaPshot assay, mutation detection sensitivity, time to progression, clinical response
- MeSH terms
- Cetuximab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Polymerase Chain Reaction, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
